WO2012052169A3 - Particulate pharmaceutical composition containing an opioid and an opioid antagonist - Google Patents

Particulate pharmaceutical composition containing an opioid and an opioid antagonist Download PDF

Info

Publication number
WO2012052169A3
WO2012052169A3 PCT/EP2011/005275 EP2011005275W WO2012052169A3 WO 2012052169 A3 WO2012052169 A3 WO 2012052169A3 EP 2011005275 W EP2011005275 W EP 2011005275W WO 2012052169 A3 WO2012052169 A3 WO 2012052169A3
Authority
WO
WIPO (PCT)
Prior art keywords
opioid
pharmaceutical composition
composition containing
opioid antagonist
particulate pharmaceutical
Prior art date
Application number
PCT/EP2011/005275
Other languages
German (de)
French (fr)
Other versions
WO2012052169A2 (en
Inventor
Lars Holger Hermann
Original Assignee
Phoeme Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoeme Gmbh filed Critical Phoeme Gmbh
Publication of WO2012052169A2 publication Critical patent/WO2012052169A2/en
Publication of WO2012052169A3 publication Critical patent/WO2012052169A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Abstract

The invention relates to a pharmaceutical composition, comprising a particle containing the opioid and the opioid antagonist, wherein the release of the opioid antagonist takes place continuously over a time period of 30 minutes up to 8 hours following oral administration, and to a dosage form containing said composition for peroral administration.
PCT/EP2011/005275 2010-10-21 2011-10-20 Particulate pharmaceutical composition containing an opioid and an opioid antagonist WO2012052169A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010236338A JP2012087101A (en) 2010-10-21 2010-10-21 Particulate pharmaceutical composition containing opioid and opioid antagonist
JP2010-236338 2010-10-21

Publications (2)

Publication Number Publication Date
WO2012052169A2 WO2012052169A2 (en) 2012-04-26
WO2012052169A3 true WO2012052169A3 (en) 2012-07-26

Family

ID=44999723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/005275 WO2012052169A2 (en) 2010-10-21 2011-10-20 Particulate pharmaceutical composition containing an opioid and an opioid antagonist

Country Status (2)

Country Link
JP (1) JP2012087101A (en)
WO (1) WO2012052169A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US9456986B2 (en) 2013-12-11 2016-10-04 Develco Pharma Schweiz Ag Naloxone mono preparation and multilayer tablet
US10105360B2 (en) 2013-12-11 2018-10-23 Develco Pharma Schweiz Ag Method and composition for the treatment of opioid induced constipation
WO2015089530A1 (en) * 2013-12-20 2015-06-25 G.L. PHARMA GmbH Extended-release oral dosage form containing morphine and naloxone
MX2021000908A (en) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Treatment of chronic cough, breathlessness and dyspnea.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058447A1 (en) * 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2007082935A1 (en) * 2006-01-19 2007-07-26 Phoenux Ag Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts
WO2009085778A1 (en) * 2007-12-17 2009-07-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
WO2010121600A2 (en) * 2009-04-22 2010-10-28 Lars Holger Hermann Particulate pharmaceutical composition having an opioid and an opioid antagonist
EP2371356A1 (en) * 2010-03-12 2011-10-05 Lars Holger Hermann Multi-particle pharmaceutical formulation for colon absorption

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058447A1 (en) * 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2007082935A1 (en) * 2006-01-19 2007-07-26 Phoenux Ag Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts
WO2009085778A1 (en) * 2007-12-17 2009-07-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
WO2010121600A2 (en) * 2009-04-22 2010-10-28 Lars Holger Hermann Particulate pharmaceutical composition having an opioid and an opioid antagonist
EP2371356A1 (en) * 2010-03-12 2011-10-05 Lars Holger Hermann Multi-particle pharmaceutical formulation for colon absorption

Also Published As

Publication number Publication date
WO2012052169A2 (en) 2012-04-26
JP2012087101A (en) 2012-05-10

Similar Documents

Publication Publication Date Title
WO2012052169A3 (en) Particulate pharmaceutical composition containing an opioid and an opioid antagonist
IL233677A (en) Substituted benzisoxazole aminopyrazolo-pyrimidine compounds, pharmaceutical compositions comprising them and use of the compounds for the manufacture of medicaments
WO2011106416A3 (en) Abuse-resistant formulations
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
WO2009114118A3 (en) Oral pharmaceutical compositions of buprenorphine and method of use
IL206835A (en) Pharmaceutical compositions comprising oil and particulate matter for oral administration of insulin and methods for preparation thereof
CO6440564A2 (en) PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE
MX2009010556A (en) Modified dosage forms of tacrolimus.
WO2010092090A3 (en) Novel salts of sitagliptin
EP2447253A4 (en) Dihydropyrimidine compounds and preparation methods, pharmaceutical compositions and uses thereof
EA201290734A1 (en) RIFAXIMIN IN THE FORM OF POWDER, THE METHOD OF ITS PRODUCTION AND THE COMPOSITION OF CONTROLLED LIBERATION CONTAINING RIFAXIMIN INDICATED, USEFUL FOR ACHIEVING A LONG-TERM EFFECT
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
HK1245139A1 (en) Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
WO2010121600A3 (en) Particulate pharmaceutical composition having an opioid and an opioid antagonist
WO2011104652A3 (en) Veterinary compositions
IL223543A (en) Pharmaceutical composition comprising1-(4-(4-(3, 4--dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-ene-1-one or pharmaceutically acceptable salt thereof and an acidic additive
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012010669A3 (en) Medicinal drug for oral administration comprising a mixture of silodosin and a basic copolymer
IL217500A0 (en) Tetrazole derivatives, their preparartion and pharmaceutical compositions containing them
PT2504331E (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
EP2560614A4 (en) Pharmaceutical compositions and methods for administering the same
WO2012074830A3 (en) Modified release tranexamic acid formulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11784937

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11784937

Country of ref document: EP

Kind code of ref document: A2